TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18843961
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 1 g thrice daily during menstrual cycle days 1-5
Study: 18843961
Drug: Norethisterone (NET)
Normalized name: ethisterone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone (NET) 5 mg twice daily on days 19-26
Study: 8695137
Drug: Nalbuphine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.25 mg/kg
Study: 1627437
Drug: Chemotherapy (CMFP)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CMFP) consisting of six 4-week cycles of cyclophosphamide (100 mg/m2 orally days 1-14), methotrexate (40 mg/m2 IV days 1 and 8), fluorouracil (600 mg/m2 IV days 1 and 8), and prednisone (40 mg/m2 orally days 1-14)
Study: 6692322
Drug: Adrenalectomy (primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenalectomy (primary and secondary therapy)
Study: 6692322
Drug: Tamoxifen (primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (primary and secondary therapy)
Study: 22581111
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (379 mg daily for 3 months)
Study: 20471761
Drug: Estrogen-only therapies
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-only therapies
Study: 20471761
Drug: Estrogen-plus-progestin therapies
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-plus-progestin therapies
Study: 17872548
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy and referral to Gamblers Anonymous (GA)
Study: 15734179
Drug: Non-directive supportive
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-directive supportive therapy (NST)
Study: 2253661
Drug: Budesonide 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3.2 mg
Study: 31509953
Drug: High-dose protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose protein regimen (scNPN)
Study: 31509953
Drug: High-dose protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose protein regimen (iNPN)
Study: 31509953
Drug: Standard-dose protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose protein regimen (scNPN)
Study: 31509953
Drug: Standard-dose protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose protein regimen (iNPN)
Study: 27884388
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml contrast medium
Study: 27884388
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml contrast medium via bolus shaping
Study: 23890352
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein (HP) diet (1.4 g protein∙kg(‐1)∙d(‐1))
Study: 23890352
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein (NP) diet (0.8 g protein∙kg(‐1)∙d(‐1))
Study: 16602255
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2) administered at 2.4 or 2.0 atmospheres absolute, preceded the chemotherapy regimen
Study: 16602255
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen (six intravenous pulses of cyclophosphamide 1000mg/m2, doxorubicin 50mg/m2, and vincristine 1.5mg/m2)
Study: 1283538
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen
Study: 16602255
Drug: Trial regime
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial regime (HBO2 + chemotherapy)
Study: 12850387
Drug: Valsartan or
Normalized name: valsartan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan or amlodipine-based treatment
Study: 10423633
Drug: Buflomedil (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil (150 mg/d intravenously)
Study: 8420016
Drug: Predictive dosing
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive dosing method
Study: 8420016
Drug: Physician dosing
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician dosing method
Study: 8420016
Drug: Individual dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual dosing method
Study: 3523328
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 to 1000 mg daily for five days)
Study: 27059951
Drug: PF‐06291874 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06291874 (150 mg once daily)
Study: 27059951
Drug: PF‐06291874 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06291874 (various doses)
Study: 18154942
Drug: Observation-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation-only treatment condition
Study: 18154942
Drug: Guided-observation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided-observation treatment condition
Study: 18154942
Drug: Instructed-observation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructed-observation treatment condition
Study: 1983610
Drug: Non-surgical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical therapy
Study: 11916603
Drug: Early atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early atropine administration
Study: 11916603
Drug: Conventional atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional atropine administration
Study: 30055974
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with omega-3 fatty acids and acipimox
Study: 30289006
Drug: Thermogenic dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thermogenic dietary supplement
Study: 20870255
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (20 to 100U, max 300U, every 3 months if necessary)
Study: 20870255
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (thiocolchicoside 16mg/day and physical rehabilitation)
Study: 18000469
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (>5.5 g/day)
Study: 8957948
Drug: Biofeedback training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback training with laxatives
Study: 8957948
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (laxatives alone)
Study: 8957948
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (biofeedback + laxatives and laxatives alone)
Study: 10136830
Drug: Oral advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral advice from nurse on producing a sputum sample (114 patients)
Study: 10136830
Drug: Oral advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral advice plus written instructions (110 patients)
Study: 3771955
Drug: Theophylline administered
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline administered intravenously
Study: 24719394
Drug: Single-dose 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 100 mg tramadol sustained-release tablets
Study: 12087523
Drug: Intranasal virosomal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal virosomal influenza vaccine
Study: 10569658
Drug: Propafenone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (600 mg for the first 24 hours, with a possible repeated dose of 300 mg for 24 hours)
Study: 10569658
Drug: Amiodarone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (30 mg/kg for the first 24 hours, with a possible repeated dose of 15 mg/kg for 24 hours)
Study: 8712137
Drug: Daily exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exercise and a low-fat diet according to the American Heart Association's recommendation phase III
Study: 1682644
Drug: Misoprostol (200-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200-1000 micrograms) after 200 mg mifepristone
Study: 31305338
Drug: Buprenorphine 0.2
Normalized name: buprenorphine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.2 mg
Study: 6990950
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg
Study: 29727332
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (capecitabine plus oxaliplatin)
Study: 27417980
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care recommendations and weekly health behavior reports for self-guided care
Study: 19651267
Drug: Pain intensity
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain intensity during injection (VAS)
Study: 23082142
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists
Study: 1289512
Drug: Atenolol (At)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (At) 50 mg/day
Study: 1289512
Drug: Nitrendipine (Ni)
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (Ni) 40 mg/day
Study: 27103031
Drug: Bilateral 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral 20 mL 0.3% ropivacaine and 2 mL dexmedetomidine (0.5 µg/kg) (group RD)
Study: 27103031
Drug: Bilateral 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral 20 mL 0.3% ropivacaine and 2 mL 0.9% normal saline (group R)
Study: 12652260
Drug: i.v. verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. verapamil (50 mg in 500 cc saline solution at 40 ml/hr)
Study: 12652260
Drug: i.v. amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. amiodarone (300 mg in bolus followed by 900 mg in 500 cc 5% glucosate solution, 33 ml/hr for 6 hours and subsequently 18 ml/hr)
Study: 15123495
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (CC) intervention
Study: 26644369
Drug: Evening intake
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening intake of rivaroxaban (10 mg)
Study: 22646064
Drug: NaP tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaP tablets
Study: 22646064
Drug: NaP tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaP tablets and PEG with sodium picosulfate
Study: 20582874
Drug: Gelatin protein
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin protein (0.6 g protein per kg bodyweight)
Study: 20216569
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (0.6 g protein per kg bodyweight)
Study: 20216569
Drug: Alpha-lactalbumin protein
Normalized name: alpha-lactalbumin (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lactalbumin protein (0.6 g protein per kg bodyweight)
Study: 20216569
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (0.6 g protein per kg bodyweight)
Study: 11818152
Drug: Cold-adapted live
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted live influenza vaccine (AA-LIV)
Study: 2099751
Drug: High-dose intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intermittent method (trt 1)
Study: 2099751
Drug: Moderate-dose continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose continuous method (trt 2)
Study: 6800028
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with synthetic human calcitonin (HCT 0.5 mg s.c./day, 5‐‐7 days per week) and EHDP (7.5 mg/kg, p.o.) for a mean duration of 6.1 months
Study: 27480431
Drug: Two phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two phase treatment (Herbst and fixed appliance)
Study: 27480431
Drug: Fixed appliance
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed appliance treatment only (edgewise appliance)
Study: 2426940
Drug: 1% permethrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% permethrin cream rinse
Study: 10688391
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g by intermittent bolus q12h
Study: 10688391
Drug: Cefepime 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 3 g by continuous infusion over 24 hours
Study: 10688391
Drug: Cefepime 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 4 g by continuous infusion over 24 hours
Study: 1511641
Drug: Subcutaneous lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lateral internal sphincterotomy
Study: 6361251
Drug: Cefamandole (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (administered intravenously after cord clamping)
Study: 16567607
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride 100 mg/d
Study: 16567607
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride 25 mg/d
Study: 11535971
Drug: Neltenexine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neltenexine (1 tablet twice daily for 20 days)
Study: 11535971
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet twice daily for 20 days)
Study: 26892612
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA‐A2+‐restricted peptides and Montanide, 6 doses every two weeks and a recall dose after 3 months
Study: 24078541
Drug: Augmented group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented group (1 ml of bone cement injected into the screw hole before insertion of the screw)
Study: 20578534
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (50.1 g total fat)
Study: 20578534
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (5.1 g total fat)
Study: 18234086
Drug: Intranasal TNFalpha
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal TNFalpha (10 microg)
Study: 12716663
Drug: DG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DG treatment (diacylglycerol-rich oil)
Study: 12716663
Drug: TG treatment
Normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG treatment (triacylglycerol-based control oil)
Study: 10683712
Drug: Tilidine/naloxone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine/naloxone (100 mg)
Study: 17766737
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of non-opioid analgesics (gabapentin and/or rofecoxib)
Study: 17766737
Drug: Morphine use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine use during the four hours preceding 8 a.m.
Study: 11798981
Drug: Steroids (mainstay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (mainstay of therapy)
Study: 11798981
Drug: Alternative agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative agents (under investigation)
Study: 7854794
Drug: Placebo: mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: mannitol 2.5 mg
Study: 1265550
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered prostaglandin E2
Study: 31055222
Drug: High-dose EPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose EPA and DHA (3.36 g daily)
Study: 19419755
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration with ADP 5 microM
Study: 19419755
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration with ADP 20 microM
Study: 10190873
Drug: Intracoronary beta-radiation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary beta-radiation therapy (90Sr/Y source train, 12, 14, or 16 Gy at 2 mm)
Study: 10190873
Drug: Intracoronary beta-radiation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary beta-radiation therapy
Study: 8525689
Drug: Oka/Merck varicella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka/Merck varicella vaccine regimen with two injections four weeks apart
Study: 8525689
Drug: Oka/Merck varicella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka/Merck varicella vaccine regimen with two injections eight weeks apart
Study: 20889289
Drug: Sedation protocol
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation protocol with daily sedative/analgesic interruption
Study: 18178380
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg/d)
Study: 18178380
Drug: D-ribose (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-ribose (2000 mg/d)
Study: 16918591
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 1700 mg/day
Study: 16918591
Drug: Thiazolidinedione (T)
Normalized name: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinedione (T) 600 mg/day
Study: 6377492
Drug: Indotard 50
Normalized name: Indotard MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indotard 50 mg given twice daily
Study: 6377492
Drug: Indocid 25
Normalized name: Indocid 25 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indocid 25 mg given four times daily
Study: 30016391
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by concurrent chemoradiotherapy (I-CCRT)
Study: 25101534
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) - 10 sessions, 830 nm, 50 mW output power, 707 J/cm² fluence; L group, n=23
Study: 25101534
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment - 10 sessions; P group, n=20
Study: 23350191
Drug: Oseltamivir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (150 mg daily for 5 days)
Study: 12144580
Drug: esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole 20 mg
Study: 12145072
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg/kg initial loading dose for 10 min; maintenance, 0.4‐0.7 microg. kg(‐1). h(‐1))
Study: 26641648
Drug: Dexmedetomidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.6 μg/kg/h)
Study: 17499988
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy for breast cancer
Study: 14998841
Drug: SuperMIP (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SuperMIP (mitomycin C 6 mg/m2; ifosfamide 4.5 g/m2; cisplatin 60 mg/m2; carboplatine 200 mg/m2)
Study: 14998841
Drug: MIP (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIP (mitomycin C 6 mg/m2; ifosfamide 3 g/m2; cisplatin 50 mg/m2)
Study: 9721778
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal suppositories alone
Study: 9721778
Drug: PGE2 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 plus Laminaria plus gel
Study: 8151058
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with 13.2 micrograms Fel d I antigen
Study: 3049213
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of nitrofurantoin
Study: 3049213
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of furazolidone
Study: 27755543
Drug: Uncontrolled abnormal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncontrolled abnormal glucose metabolism (AGM) among pre-diagnosed diabetic cases
Study: 25447748
Drug: Thermal cure
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal cure (spa treatment including underwater shower, massage-jet showers, hydromassage, pool rehabilitation, and peloid therapy)
Study: 25447748
Drug: Non-thermal rehabilitation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-thermal rehabilitation (analgesic physiotherapy, muscle strengthening, and group physical rehabilitation)
Study: 20408861
Drug: Oral NTHi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NTHi treatment
Study: 18202420
Drug: Urokinase rinses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase rinses (5 mL of 5,000 U/mL) three times weekly
Study: 18202420
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) three times weekly
Study: 11056121
Drug: Stop protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop protocol (GnRHa administration stopped with the onset of menses, high doses of gonadotrophins)
Study: 11056121
Drug: Non-stop protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-stop protocol (long GnRHa suppression with high doses of gonadotrophins)
Study: 3987071
Drug: Naloxone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (15 mg infusion)
Study: 3987071
Drug: Naloxone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (30 mg infusion)